Literature DB >> 29141125

Elevated Proinflammatory Markers in 22q11.2 Deletion Syndrome Are Associated With Psychosis and Cognitive Deficits.

Ehud Mekori-Domachevsky1,2,3, Michal Taler2,4, Yehuda Shoenfeld2,5, Michael Gurevich6, Polina Sonis6, Omri Weisman2,3, Abraham Weizman2,4,7, Doron Gothelf2,3.   

Abstract

OBJECTIVE: 22q11.2 deletion syndrome (22q11.2DS) is a neurogenetic disorder whose phenotype includes high rates of a schizophrenia-like psychotic disorder and immune system abnormalities. Thus, 22q11.2DS is an ideal model for studying the relationship between psychosis and inflammation. The aim of the present study was to identify inflammatory markers that may play a role in the pathophysiologic pathways associated with psychosis and cognitive deficits in 22q11.2DS.
METHODS: Forty-nine individuals with 22q11.2DS (13 with psychotic disorders according to DSM-IV criteria and 36 without psychotic disorders) and 30 age- and sex-matched healthy controls underwent psychiatric and cognitive assessments at an outpatient clinic. Blood samples from all participants were analyzed for C-reactive protein (CRP), interleukin (IL)-6, IL-10, tumor necrosis factor alpha (TNFα), and IL-1 receptor antagonist levels. The study was conducted between August 2014 and September 2015.
RESULTS: The 22q11.2DS participants had elevated levels of CRP (P = .004), IL-6 (P = .001), TNFα (P < .001), and IL-10 (P = .028) compared with controls. Furthermore, the psychotic 22q11.2DS participants had higher levels of IL-6 (P < .001) and IL-6/IL-10 ratio (used as an indicator for proinflammatory activation, P < .001) compared with the nonpsychotic 22q11.2DS individuals and controls. IL-6 levels and the IL-6/IL-10 ratio correlated with the severity of the cognitive deficits in the 22q11.2DS participants.
CONCLUSIONS: Our preliminary findings indicate an involvement of inflammatory processes in the pathophysiology of psychosis and cognitive deficits in 22q11.2DS and are in line with the accumulating evidence for the role of neuroinflammation in nonsyndromic schizophrenia. © Copyright 2017 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29141125     DOI: 10.4088/JCP.16m11207

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  4 in total

1.  A pilot study on immuno-psychiatry in the 22q11.2 deletion syndrome: A role for Th17 cells in psychosis?

Authors:  Elfi Vergaelen; Carmen Schiweck; Kristof Van Steeland; Jacqueline Counotte; Wim Veling; Ann Swillen; Hemmo Drexhage; Stephan Claes
Journal:  Brain Behav Immun       Date:  2018-03-19       Impact factor: 7.217

2.  Association of a functional Claudin-5 variant with schizophrenia in female patients with the 22q11.2 deletion syndrome.

Authors:  Yiran Guo; Larry N Singh; Yuankun Zhu; Raquel E Gur; Adam Resnick; Stewart A Anderson; Jorge I Alvarez
Journal:  Schizophr Res       Date:  2019-10-23       Impact factor: 4.939

3.  Disruption of the blood-brain barrier in 22q11.2 deletion syndrome.

Authors:  Alexis M Crockett; Sean K Ryan; Adriana Hernandez Vásquez; Caroline Canning; Nickole Kanyuch; Hania Kebir; Guadalupe Ceja; James Gesualdi; Elaine Zackai; Donna McDonald-McGinn; Angela Viaene; Richa Kapoor; Naïl Benallegue; Raquel Gur; Stewart A Anderson; Jorge I Alvarez
Journal:  Brain       Date:  2021-06-22       Impact factor: 13.501

4.  Autoinflammatory Keratinization Disease With Hepatitis and Autism Reveals Roles for JAK1 Kinase Hyperactivity in Autoinflammation.

Authors:  Takuya Takeichi; John Y W Lee; Yusuke Okuno; Yuki Miyasaka; Yuya Murase; Takenori Yoshikawa; Kana Tanahashi; Emi Nishida; Tatsuya Okamoto; Komei Ito; Yoshinao Muro; Kazumitsu Sugiura; Tamio Ohno; John A McGrath; Masashi Akiyama
Journal:  Front Immunol       Date:  2022-01-03       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.